Celiac Disease Explained: HLA Genetics, Villous Atrophy, and Diagnosis

A Disease That Hides for Decades

The average diagnostic delay for celiac disease in the United States is approximately 6–10 years from symptom onset, according to a 2016 survey by the Celiac Disease Foundation — despite the fact that roughly 1% of the global population carries the condition, translating to about 3 million Americans. The disease causes the immune system to attack the small intestinal lining in response to dietary gluten, a protein complex found in wheat, barley, and rye. The damage accumulates silently or with symptoms so nonspecific — bloating, fatigue, iron deficiency, bone pain — that physicians frequently attribute them to irritable bowel syndrome or stress before ordering the correct tests.

The Genetic Prerequisite

Celiac disease cannot develop without specific HLA class II genes: HLA-DQ2 (encoded by DQA1*05 and DQB1*02 alleles) or HLA-DQ8 (DQA1*03 and DQB1*0302). These genes are present in approximately 30–35% of the general population, but only 1–3% of those with the genetic susceptibility actually develop celiac disease — meaning genetic testing is useful for ruling out the condition (negative predictive value >99%) but cannot diagnose it. The HLA proteins present gluten-derived peptides to CD4+ T cells in the lamina propria; the resulting immune cascade drives both intestinal damage and systemic effects.

Why only some genetically susceptible individuals develop the disease remains under investigation. Environmental triggers under study include early-life antibiotic use, rotavirus infection, early or late gluten introduction in infancy, and the composition of the gut microbiome. The "hygiene hypothesis" — that reduced early infectious exposure alters immune regulation — may account for rising celiac prevalence in industrialized countries over the past 50 years.

Intestinal Pathology: Villous Atrophy

The diagnostic gold standard for celiac disease remains duodenal biopsy, graded by the Marsh-Oberhuber classification:

Villous atrophy reduces the mucosal surface area available for nutrient absorption by up to 90%. The resulting malabsorption drives the classic complications: iron deficiency (proximal duodenum is the primary iron absorption site), calcium and vitamin D malabsorption causing osteoporosis, and folate deficiency causing megaloblastic anemia.

Fasano's Zonulin Research

Dr. Alessio Fasano's laboratory at the University of Maryland (research published beginning 2000) identified zonulin as a protein upregulated by gliadin exposure in the gut. Zonulin modulates tight junction permeability between intestinal epithelial cells, and elevated zonulin levels correlate with increased intestinal permeability — colloquially called "leaky gut." In active celiac disease, gliadin triggers zonulin release even before immune-mediated damage, potentially explaining how luminal antigens reach lamina propria immune cells. Fasano's group also found elevated zonulin in type 1 diabetes and multiple sclerosis, suggesting a broader role for intestinal permeability in autoimmune disease pathogenesis. A zonulin-blocking drug (larazotide acetate) reduced celiac symptoms in phase 2 trials but failed to demonstrate sufficient efficacy for regulatory approval.

Serological Testing

• Anti-tissue transglutaminase IgA (tTG-IgA): Sensitivity 93–98%, specificity 96–99%; first-line test. IgA deficiency (affects 1 in 300 people, 10× more common in celiac patients) produces false negatives — total IgA should always be checked simultaneously.
• Anti-endomysial antibody IgA (EMA-IgA): Specificity ~99.5%; used as confirmatory test; observer-dependent immunofluorescence.
• Deamidated gliadin peptide IgG (DGP-IgG): Best test for IgA-deficient individuals and children under 2 years.

Non-Celiac Gluten Sensitivity: A Different Entity

Non-celiac gluten sensitivity (NCGS) describes symptoms triggered by gluten in the absence of celiac autoantibodies, HLA-DQ2/DQ8 genes, or villous atrophy. The condition was validated in a double-blind crossover study by Biesiekierski et al. (2011, American Journal of Gastroenterology) — but the same group's 2013 follow-up study, a meticulous rechallenge design controlling for FODMAPs (fermentable carbohydrates also present in wheat), found no specific gluten effect. Current evidence suggests most "gluten sensitivity" is actually FODMAP sensitivity, though a genuine gluten-specific innate immune response may exist in a subset of patients. NCGS carries no demonstrated risk of villous atrophy, autoantibody formation, or HLA genetic requirement.

Refractory Celiac Disease

Approximately 1–2% of celiac disease patients fail to respond to a strict gluten-free diet (confirmed adherence). Refractory celiac disease type I features normal intraepithelial lymphocyte (IEL) phenotype; type II features aberrant IEL clones with loss of surface CD3 and CD8 — a condition that confers up to 50% 5-year mortality due to progression to enteropathy-associated T-cell lymphoma (EATL). Management of type II includes immunosuppressive therapy (steroids, azathioprine) and experimental approaches including cladribine and auto-SCT in specialized centers.

This article is for informational purposes only. Consult a qualified healthcare professional.